Pliant Therapeutics Inc. (PLRX)
Company Description
Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States.
Its lead product candidate is PLN-74809, an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins, which is in three Phase 2a trials.
The company also develops PLN-1474, a small-molecule selective inhibitor of avß1, which completed Phase 1 clinical trial for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis.
In addition, it is developing two additional preclinical integrin-based programs, which include an oncology program, as well as a program for an allosteric agonistic monoclonal antibody against an undisclosed integrin receptor for treatment of muscular dystrophies, including duchenne muscular dystrophy.
Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.

Country | United States |
IPO Date | Jun 3, 2020 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 171 |
CEO | Dr. Bernard Coulie M.B.A., M.D., Ph.D. |
Contact Details
Address: 260 Littlefield Avenue South San Francisco, California United States | |
Website | https://pliantrx.com |
Stock Details
Ticker Symbol | PLRX |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001746473 |
CUSIP Number | 729139105 |
ISIN Number | US7291391057 |
Employer ID | 47-4272481 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Dr. Bernard Coulie M.B.A., M.D., Ph.D. | President, Chief Executive Officer & Director |
Dr. Keith Lamont Cummings M.B.A., M.D. | Chief Financial Officer |
Bill DeGrado Ph.D. | Scientific Founder & Member of Scientific Advisory Board |
Christopher S. Keenan | Vice President of Investor Relations & Corporate Communications |
Dean Sheppard M.D. | Scientific Founder & Member of Scientific Advisory Board |
Delphine Imbert Ph.D. | Chief Technical Officer |
Dr. Eric A. Lefebvre M.D. | Chief Medical Officer |
Dr. Rik Derynck Ph.D. | Scientific Founder & Member of Scientific Advisory Board |
Hal Chapman M.D. | Scientific Founder & Member of Scientific Advisory Board |
Johannes P. Hull J.D. | Chief Business Officer |
Latest SEC Filings
Date | Type | Title |
---|---|---|
May 15, 2025 | SCHEDULE 13G/A | [Amend] Filing |
May 14, 2025 | SCHEDULE 13G/A | [Amend] Filing |
May 08, 2025 | 10-Q | Quarterly Report |
May 08, 2025 | 8-K | Current Report |
May 01, 2025 | 8-K | Current Report |
Apr 23, 2025 | DEFA14A | Filing |
Apr 23, 2025 | DEF 14A | Filing |
Apr 11, 2025 | PRER14A | Filing |
Apr 10, 2025 | PRE 14A | Filing |
Mar 13, 2025 | 8-K | Current Report |